Suzano S.A. Form 6-K Summary
Business Context and Reporting Period
Company: Suzano S.A. (Suzano)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2026 (Unaudited)
Business Overview: Suzano is a global leader in the production of hardwood pulp, paper, and consumer goods (tissue). Operations include 15 industrial units (13 in Brazil, 2 in the U.S.) and a global logistics network. The company is controlled by Suzano Holding S.A., which held 48.85% of common shares as of June 30, 2026.
Key Financial Metrics (Six Months YTD)
| Metric (R$ Thousands) | 2026 YTD | 2025 YTD |
|---|---|---|
| Net Sales | 22,558,549 | 24,848,816 |
| Gross Profit | 5,989,508 | 8,511,525 |
| Operating Profit (Pre-Net Financial) | 4,563,767 | 5,134,179 |
| Net Income (Attributable to Controlling) | 6,105,965 | 11,345,455 |
| Adjusted EBITDA | 9,284,751 | 10,953,192 |
| Cash from Operating Activities | 7,269,343 | 8,758,265 |
| Cash and Cash Equivalents (End of Period) | 16,645,571 | 12,283,589 |
| Total Debt (Loans, Financing, Debentures) | 92,706,122 | 94,801,257 |
Note: All figures are in thousands of Brazilian Reais (R$). Net financial result for 2026 YTD was R$4.6 billion, significantly lower than R$12.1 billion in 2025, primarily due to reduced monetary and exchange variations.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9.2% to R$22.6 billion, driven by lower pulp volumes and prices. Pulp segment sales fell to R$17.1 billion from R$18.9 billion.
- Profitability Compression: Net income attributable to controlling shareholders dropped 46.2% to R$6.1 billion. This was largely due to a significant reduction in net financial income (exchange rate gains and derivative results) compared to the prior year.
- Biological Assets Gain: The company recognized a fair value gain of R$1.16 billion on biological assets (eucalyptus forests), partially offsetting operational headwinds.
- Debt Reduction: Total loans and financing decreased slightly to R$92.7 billion from R$94.8 billion, despite new issuances, due to principal repayments and exchange rate effects.
- Liquidity Improvement: Cash and cash equivalents increased by R$1.47 billion to R$16.6 billion, bolstered by strong operating cash flow and a new Revolving Credit Facility.
Guidance, Outlook, and Risks
- Major Acquisition (Subsequent Event): On July 1, 2026, Suzano completed the acquisition of a 51% interest in Arbex (a global tissue business formerly owned by Kimberly-Clark). The transaction included 22 production facilities in 14 countries. The cash consideration was reduced to US$1.293 billion (approx. R$6.69 billion) following funding arrangements. Arbex will be consolidated prospectively from July 1, 2026.
- Geopolitical Risks: Management monitors the Middle East crisis, noting increased volatility in energy and commodity costs. No material operational impacts were identified as of June 30, 2026.
- Tax Contingencies: Significant uncertainties remain regarding income tax treatments. A Tax Assessment Notice received in April 2026 regarding foreign earnings (Austria subsidiary) has an estimated exposure of R$5.18 billion. Total probable tax contingencies amount to R$10.06 billion.
- Climate and Sustainability: The company missed its GHG emissions intensity target for the period, resulting in a 25-basis-point step-up in the interest rate of its 2031 Sustainability-Linked Bond (SLB).
- Financial Risk Management: The company maintains a conservative hedging policy. Sensitivity analysis indicates that a 25% depreciation of the Brazilian Real against the US Dollar would negatively impact profit or loss by approximately R$16.3 billion on net debt positions.
Investor Verification Checklist
- Arbex Integration: Verify the final purchase price allocation and the impact of the Arbex acquisition on full-year 2026 revenue and EBITDA guidance.
- Tax Litigation Exposure: Review the status of the R$5.18 billion tax assessment regarding the Austria subsidiary and the R$10 billion total probable tax contingencies.
- Exchange Rate Sensitivity: Assess the impact of BRL/USD fluctuations on the company's net debt position and future earnings, given the high exposure to foreign currency debt.
- Biological Asset Valuation: Confirm the assumptions used for the R$1.16 billion fair value gain on biological assets (growth rates, wood prices, discount rates).
- Debt Maturity Profile: Analyze the maturity schedule of the R$92.7 billion debt portfolio, particularly the concentration of foreign currency bonds and export credits.